Physician profile
Hrair Simonian
NPI 1861502973
$15,181.68
in general payments reported to CMS, 2019-2025
38 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $1,429 · 2021: $2,142 · 2022: $2,043 · 2023: $1,712 · 2024: $3,801 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,794 · Travel and Lodging: $907 · Gift: $164 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,794.11 |
| Travel and Lodging | $906.88 |
| Gift | $163.62 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,143.39 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $3,471.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Medtronic, INC. | $1,231.63 | 2024 | Interstim |
| Janssen Biotech, INC. | $717.44 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $691.51 | 2021-2024 | Linzess |
| Gilead Sciences, INC. | $659.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $641.69 | 2019-2025 | Gattex, Entyvio |
| Intercept Pharmaceuticals, INC. | $475.21 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $349.03 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $306.89 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $244.39 | 2021-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $220.56 | 2020-2021 | |
| Pfizer INC. | $213.10 | 2020-2025 | |
| Ardelyx, INC. | $208.98 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $181.68 | 2024-2025 | Omvoh |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $169.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $163.62 | 2024 | Sutab, Suflave |
| Allergan, INC. | $161.42 | 2019 | |
| Genzyme Corporation | $132.53 | 2023-2024 | |
| Boston Scientific Corporation | $104.76 | 2023-2025 | Radial Jaw 4, Cre Pro |
| Olympus America INC. | $93.10 | 2023 | Evis Exera III Gastrointestinal Videoscope, Evis Exera Lll Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $92.95 | 2024 | Voquezna |
| Celgene Corporation | $92.69 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $89.98 | 2025 | Iqirvo |
| Amgen INC. | $74.89 | 2020-2022 | |
| Vivus LLC | $44.11 | 2021-2022 | |
| Mauna Kea Technologies, INC. | $29.30 | 2025 | |
| Globus Medical, INC. | $27.86 | 2025 | Senza |
| Axonics, INC. | $22.00 | 2024 | Axonics |
| Nestle Healthcare Nutrition INC. | $18.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2023 | Cyltezo |
| Novo Nordisk INC | $15.72 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $14.55 | 2021 | |
| Enterra Medical, INC. | $13.58 | 2022 | |
| Shionogi INC | $12.37 | 2019 | |
| Pharmacosmos Therapeutics INC. | $11.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.70 | 2020 | |
| Alfasigma USA, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hrair Simonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.